Table 1.

Randomized trials of adjuvant radiation therapy in stage I endometrial carcinoma

Trial (ref) accrual period	No. patients eligibility	Surgery	Randomization	Locoregional recurrence	Survival
Norwegian [11] 1968–1974	540 Stage I	TAH-BSO	VBT vs VBT + pelvic RT	7% vs 2% at 5 years P < 0.01	89% vs 91% at 5 years P = NS
PORTEC-1 [9] 1990–1997	714 IB grade 2–3 IC grade 1–2	TAH-BSO	NAT vs pelvic RT	14% vs 4% at 5 years P < 0.001	85% vs 81% at 5 years P = 0.31
GOG-99 [10] 1987–1995	392 Stage IB, IC Stage II (occult)	TAH-BSO and lymphadenectomy	NAT vs pelvic RT	12% vs 3% at 2 years P < 0.01	86% vs 92% at 4 years P = 0.56
ASTEC/EN5 [12••] 1996–2005	905 Stage IAB g3, IC, Stage II, serous/cc	TAH-BSO ± lymphadenectomy	NAT vs pelvic RT	7%a vs 4% at 5 years P = 0.038	84% vs 84% at 5 years P = 0.98
PORTEC-2 [21••] 2002–2006	427, age >60 IB grade 3 IC grade 1–2	TAH-BSO	VBT vs pelvic RT	2% vs 2% at 5 years P = 0.74	85% vs 80% at 5 years P = 0.57

^a53% in NAT arm received VBT; isolated locoregional recurrence reported

NAT no additional treatment; RT radiation therapy; VBT vaginal brachytherapy